Drugs / SYT-510
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06670950 | Nov 2024 → May 2025 | — | Synendos Therapeutics AG | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07478744 | Apr 2026 → Jan 2027 expected | generalized anxiety disorder | Synendos Therapeutics AG | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-09-24 | Synendos Therapeutics AG | Results September 2025 synendos.com ↗
Synendos Therapeutics (“Synendos”), the clinical-stage biotech company developing breakthrough therapies for neuropsychiatric disorders, announced today topline results for its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the Endocannabinoid System that helps restore healthy brain functions. |
| 2024-01-18 | Synendos Therapeutics AG | Regulatory January 2024 synendos.com ↗
Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-24 | Synendos Therapeutics AG | September 2025 synendos.com ↗ |
| 2024-01-18 | Synendos Therapeutics AG | January 2024 synendos.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYT-510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06670950 ↗ |
| Route | Oral | “following oral administration of SYT-510” NCT06670950 ↗ |